世界のファーマコゲノミクス技術・セラノスティクス・コンパニオン診断（CDx）市場 2021：企業別、地域別、種類・用途別

• 英文タイトル：Global Pharmacogenomics Technology & Theranostics & Companion Diagnostics (CDx) Market 2021 by Company, Regions, Type and Application, Forecast to 2026

• レポートコード：GIR-107A12574 • 出版社/出版日：GlobalInfoResearch / 2021年7月 ※2024年版があります。お問い合わせください。 • レポート形態：英文、PDF、84ページ • 納品方法：Eメール（納期：2~3日） • 産業分類：医療

• 販売価格（消費税別）

Single User	￥515,040 (USD3,480)	▷ お問い合わせ
Multi User	￥772,560 (USD5,220)	▷ お問い合わせ
Corporate User	￥1,030,080 (USD6,960)	▷ お問い合わせ

• ご注文方法：お問い合わせフォーム記入又はEメールでご連絡ください。
• お支払方法：銀行振込（納品後、ご請求書送付）

---

レポート概要

---

当調査資料では、ファーマコゲノミクス技術・セラノスティクス・コンパニオン診断（CDx）のグローバル市場について調査・分析し、2021年から2026年までの市場予測をまとめております。ファーマコゲノミクス技術・セラノスティクス・コンパニオン診断（CDx）の種類別市場規模（PCR、in-situハイブリダイゼーション、免疫組織化学、シーケンシング、その他）、用途別市場規模（腫瘍、神経障害、心血管疾患、免疫障害、その他）、地域別市場規模（北米、アメリカ、ヨーロッパ、アジア、中国、日本、東南アジア、南米、中東、アフリカなど）、市場動向、企業別販売量と市場シェア、販売チャネルなどの情報を掲載しています。 ・ファーマコゲノミクス技術・セラノスティクス・コンパニオン診断（CDx）の市場概要 ・企業情報（企業概要、製品概要、販売量、価格、売上）：Qiagen NV、GE Healthcare、Agilent Technologies、F Hoffman La Roche、Foundation Medicine、Thermo Fisher Scientific Inc.、Leica Biosystems Nussloch GmBH、Pfizer ・企業別市場シェア ・地域別市場分析2016年-2026年 ・種類別分析2016年-2026年：PCR、in-situハイブリダイゼーション、免疫組織化学、シーケンシング、その他 ・用途別分析2016年-2026年：腫瘍、神経障害、心血管疾患、免疫障害、その他 ・ファーマコゲノミクス技術・セラノスティクス・コンパニオン診断（CDx）の北米市場規模2016年-2026年：アメリカ、カナダ、メキシコ ・ファーマコゲノミクス技術・セラノスティクス・コンパニオン診断（CDx）のヨーロッパ市場規模2016年-2026年：ドイツ、イギリス、フランス、ロシア、イタリア ・ファーマコゲノミクス技術・セラノスティクス・コンパニオン診断（CDx）のアジア市場規模2016年-2026年：中国、日本、韓国、インド、東南アジア、オーストラリア ・ファーマコゲノミクス技術・セラノスティクス・コンパニオン診断（CDx）の南米市場規模2016年-2026年：ブラジル、アルゼンチン ・ファーマコゲノミクス技術・セラノスティクス・コンパニオン診断（CDx）の中東・アフリカ市場規模2016年-2026年：サウジアラビア、トルコ、エジプト、南アフリカ ・販売チャネル、流通業者・代理店、顧客リスト ・調査の結果・結論

The Pharmacogenomics Technology & Theranostics & Companion Diagnostics (CDx) market report provides a detailed analysis of global market size, regional and country-level market size, segmentation market growth, market share, competitive Landscape, sales analysis, impact of domestic and global market players, value chain optimization, trade regulations, recent developments, opportunities analysis, strategic market growth analysis, product launches, area marketplace expanding, and technological innovations.

According to our latest research, the global Pharmacogenomics Technology & Theranostics & Companion Diagnostics (CDx) size is estimated to be USD 6884.5 million in 2026 from USD 5330.8 million in 2020, with a change XX% between 2020 and 2021. The global Pharmacogenomics Technology & Theranostics & Companion Diagnostics (CDx) market size is expected to grow at a CAGR of 6.6% for the next five years.

Market segmentation
Pharmacogenomics Technology & Theranostics & Companion Diagnostics (CDx) market is split by Type and by Application. For the period 2016-2026, the growth among segments provide accurate calculations and forecasts for revenue by Type and by Application. This analysis can help you expand your business by targeting qualified niche markets.

Market segment by Type, covers
PCR
In-situ Hybridization
Immunohistochemistry
Sequencing
Others

Market segment by Application, can be divided into
Oncology
Neurological Disorders
Cardiovascular Disease
Immunological Disorders
Others

Market segment by players, this report covers
Qiagen NV
GE Healthcare
Agilent Technologies
F Hoffman La Roche
Foundation Medicine
Thermo Fisher Scientific Inc.
Leica Biosystems Nussloch GmBH
Pfizer

Market segment by regions, regional analysis covers
North America (United States, Canada, and Mexico)
Europe (Germany, France, UK, Russia, Italy, and Rest of Europe)
Asia-Pacific (China, Japan, South Korea, India, Southeast Asia, Australia, and Rest of Asia-Pacific)
South America (Brazil, Argentina, Rest of South America)
Middle East & Africa (Turkey, Saudi Arabia, UAE, Rest of Middle East & Africa)

The content of the study subjects, includes a total of 12 chapters:
Chapter 1, to describe Pharmacogenomics Technology & Theranostics & Companion Diagnostics (CDx) product scope, market overview, market opportunities, market driving force and market risks.
Chapter 2, to profile the top players of Pharmacogenomics Technology & Theranostics & Companion Diagnostics (CDx), with revenue, gross margin and global market share of Pharmacogenomics Technology & Theranostics & Companion Diagnostics (CDx) from 2019 to 2021.
Chapter 3, the Pharmacogenomics Technology & Theranostics & Companion Diagnostics (CDx) competitive situation, revenue and global market share of top players are analyzed emphatically by landscape contrast.
Chapter 4 and 5, to segment the market size by type and application, with revenue and growth rate by type, application, from 2016 to 2026.
Chapter 6, 7, 8, 9, and 10, to break the market size data at the country level, with revenue and market share for key countries in the world, from 2016 to 2021.and Pharmacogenomics Technology & Theranostics & Companion Diagnostics (CDx) market forecast, by regions, type and application, with revenue, from 2021 to 2026.
Chapter 11 and 12, to describe Pharmacogenomics Technology & Theranostics & Companion Diagnostics (CDx) research findings and conclusion, appendix and data source.

レポート目次

---

1 Market Overview
1.1 Product Overview and Scope of Pharmacogenomics Technology & Theranostics & Companion Diagnostics (CDx)
1.2 Classification of Pharmacogenomics Technology & Theranostics & Companion Diagnostics (CDx) by Type
1.2.1 Overview: Global Pharmacogenomics Technology & Theranostics & Companion Diagnostics (CDx) Market Size by Type: 2020 Versus 2021 Versus 2026
1.2.2 Global Pharmacogenomics Technology & Theranostics & Companion Diagnostics (CDx) Revenue Market Share by Type in 2020
1.2.3 PCR
1.2.4 In-situ Hybridization
1.2.5 Immunohistochemistry
1.2.6 Sequencing
1.2.7 Others
1.3 Global Pharmacogenomics Technology & Theranostics & Companion Diagnostics (CDx) Market by Application
1.3.1 Overview: Global Pharmacogenomics Technology & Theranostics & Companion Diagnostics (CDx) Market Size by Application: 2020 Versus 2021 Versus 2026
1.3.2 Oncology
1.3.3 Neurological Disorders
1.3.4 Cardiovascular Disease
1.3.5 Immunological Disorders
1.3.6 Others
1.4 Global Pharmacogenomics Technology & Theranostics & Companion Diagnostics (CDx) Market Size & Forecast
1.5 Global Pharmacogenomics Technology & Theranostics & Companion Diagnostics (CDx) Market Size and Forecast by Region
1.5.1 Global Pharmacogenomics Technology & Theranostics & Companion Diagnostics (CDx) Market Size by Region: 2016 VS 2021 VS 2026
1.5.2 Global Pharmacogenomics Technology & Theranostics & Companion Diagnostics (CDx) Market Size by Region, (2016-2021)
1.5.3 North America Pharmacogenomics Technology & Theranostics & Companion Diagnostics (CDx) Market Size and Prospect (2016-2026)
1.5.4 Europe Pharmacogenomics Technology & Theranostics & Companion Diagnostics (CDx) Market Size and Prospect (2016-2026)
1.5.5 Asia-Pacific Pharmacogenomics Technology & Theranostics & Companion Diagnostics (CDx) Market Size and Prospect (2016-2026)
1.5.6 South America Pharmacogenomics Technology & Theranostics & Companion Diagnostics (CDx) Market Size and Prospect (2016-2026)
1.5.7 Middle East and Africa Pharmacogenomics Technology & Theranostics & Companion Diagnostics (CDx) Market Size and Prospect (2016-2026)
1.6 Market Drivers, Restraints and Trends
1.6.1 Pharmacogenomics Technology & Theranostics & Companion Diagnostics (CDx) Market Drivers
1.6.2 Pharmacogenomics Technology & Theranostics & Companion Diagnostics (CDx) Market Restraints
1.6.3 Pharmacogenomics Technology & Theranostics & Companion Diagnostics (CDx) Trends Analysis
2 Company Profiles
2.1 Qiagen NV
2.1.1 Qiagen NV Details
2.1.2 Qiagen NV Major Business
2.1.3 Qiagen NV Pharmacogenomics Technology & Theranostics & Companion Diagnostics (CDx) Product and Solutions
2.1.4 Qiagen NV Pharmacogenomics Technology & Theranostics & Companion Diagnostics (CDx) Revenue, Gross Margin and Market Share (2019-2021)
2.1.5 Qiagen NV Recent Developments and Future Plans
2.2 GE Healthcare
2.2.1 GE Healthcare Details
2.2.2 GE Healthcare Major Business
2.2.3 GE Healthcare Pharmacogenomics Technology & Theranostics & Companion Diagnostics (CDx) Product and Solutions
2.2.4 GE Healthcare Pharmacogenomics Technology & Theranostics & Companion Diagnostics (CDx) Revenue, Gross Margin and Market Share (2019-2021)
2.2.5 GE Healthcare Recent Developments and Future Plans
2.3 Agilent Technologies
2.3.1 Agilent Technologies Details
2.3.2 Agilent Technologies Major Business
2.3.3 Agilent Technologies Pharmacogenomics Technology & Theranostics & Companion Diagnostics (CDx) Product and Solutions
2.3.4 Agilent Technologies Pharmacogenomics Technology & Theranostics & Companion Diagnostics (CDx) Revenue, Gross Margin and Market Share (2019-2021)
2.3.5 Agilent Technologies Recent Developments and Future Plans
2.4 F Hoffman La Roche
2.4.1 F Hoffman La Roche Details
2.4.2 F Hoffman La Roche Major Business
2.4.3 F Hoffman La Roche Pharmacogenomics Technology & Theranostics & Companion Diagnostics (CDx) Product and Solutions
2.4.4 F Hoffman La Roche Pharmacogenomics Technology & Theranostics & Companion Diagnostics (CDx) Revenue, Gross Margin and Market Share (2019-2021)
2.4.5 F Hoffman La Roche Recent Developments and Future Plans
2.5 Foundation Medicine
2.5.1 Foundation Medicine Details
2.5.2 Foundation Medicine Major Business
2.5.3 Foundation Medicine Pharmacogenomics Technology & Theranostics & Companion Diagnostics (CDx) Product and Solutions
2.5.4 Foundation Medicine Pharmacogenomics Technology & Theranostics & Companion Diagnostics (CDx) Revenue, Gross Margin and Market Share (2019-2021)
2.5.5 Foundation Medicine Recent Developments and Future Plans
2.6 Thermo Fisher Scientific Inc.
2.6.1 Thermo Fisher Scientific Inc. Details
2.6.2 Thermo Fisher Scientific Inc. Major Business
2.6.3 Thermo Fisher Scientific Inc. Pharmacogenomics Technology & Theranostics & Companion Diagnostics (CDx) Product and Solutions
2.6.4 Thermo Fisher Scientific Inc. Pharmacogenomics Technology & Theranostics & Companion Diagnostics (CDx) Revenue, Gross Margin and Market Share (2019-2021)
2.6.5 Thermo Fisher Scientific Inc. Recent Developments and Future Plans
2.7 Leica Biosystems Nussloch GmBH
2.7.1 Leica Biosystems Nussloch GmBH Details
2.7.2 Leica Biosystems Nussloch GmBH Major Business
2.7.3 Leica Biosystems Nussloch GmBH Pharmacogenomics Technology & Theranostics & Companion Diagnostics (CDx) Product and Solutions
2.7.4 Leica Biosystems Nussloch GmBH Pharmacogenomics Technology & Theranostics & Companion Diagnostics (CDx) Revenue, Gross Margin and Market Share (2019-2021)
2.7.5 Leica Biosystems Nussloch GmBH Recent Developments and Future Plans
2.8 Pfizer
2.8.1 Pfizer Details
2.8.2 Pfizer Major Business
2.8.3 Pfizer Pharmacogenomics Technology & Theranostics & Companion Diagnostics (CDx) Product and Solutions
2.8.4 Pfizer Pharmacogenomics Technology & Theranostics & Companion Diagnostics (CDx) Revenue, Gross Margin and Market Share (2019-2021)
2.8.5 Pfizer Recent Developments and Future Plans
3 Market Competition, by Players
3.1 Global Pharmacogenomics Technology & Theranostics & Companion Diagnostics (CDx) Revenue and Share by Players (2019-2021)
3.2 Market Concentration Rate
3.2.1 Top 3 Pharmacogenomics Technology & Theranostics & Companion Diagnostics (CDx) Players Market Share
3.2.2 Top 10 Pharmacogenomics Technology & Theranostics & Companion Diagnostics (CDx) Players Market Share
3.2.3 Market Competition Trend
3.3 Pharmacogenomics Technology & Theranostics & Companion Diagnostics (CDx) Players Head Office, Products and Services Provided
3.4 Mergers & Acquisitions
3.5 New Entrants and Expansion Plans
4 Market Size Segment by Type
4.1 Global Pharmacogenomics Technology & Theranostics & Companion Diagnostics (CDx) Revenue and Market Share by Type (2016-2021)
4.2 Global Pharmacogenomics Technology & Theranostics & Companion Diagnostics (CDx) Market Forecast by Type (2021-2026)
5 Market Size Segment by Application
5.1 Global Pharmacogenomics Technology & Theranostics & Companion Diagnostics (CDx) Revenue Market Share by Application (2016-2021)
5.2 Pharmacogenomics Technology & Theranostics & Companion Diagnostics (CDx) Market Forecast by Application (2021-2026)
6 North America by Country, by Type, and by Application
6.1 North America Pharmacogenomics Technology & Theranostics & Companion Diagnostics (CDx) Revenue by Type (2016-2026)
6.2 North America Pharmacogenomics Technology & Theranostics & Companion Diagnostics (CDx) Revenue by Application (2016-2026)
6.3 North America Pharmacogenomics Technology & Theranostics & Companion Diagnostics (CDx) Market Size by Country
6.3.1 North America Pharmacogenomics Technology & Theranostics & Companion Diagnostics (CDx) Revenue by Country (2016-2026)
6.3.2 United States Pharmacogenomics Technology & Theranostics & Companion Diagnostics (CDx) Market Size and Forecast (2016-2026)
6.3.3 Canada Pharmacogenomics Technology & Theranostics & Companion Diagnostics (CDx) Market Size and Forecast (2016-2026)
6.3.4 Mexico Pharmacogenomics Technology & Theranostics & Companion Diagnostics (CDx) Market Size and Forecast (2016-2026)
7 Europe by Country, by Type, and by Application
7.1 Europe Pharmacogenomics Technology & Theranostics & Companion Diagnostics (CDx) Revenue by Type (2016-2026)
7.2 Europe Pharmacogenomics Technology & Theranostics & Companion Diagnostics (CDx) Revenue by Application (2016-2026)
7.3 Europe Pharmacogenomics Technology & Theranostics & Companion Diagnostics (CDx) Market Size by Country
7.3.1 Europe Pharmacogenomics Technology & Theranostics & Companion Diagnostics (CDx) Revenue by Country (2016-2026)
7.3.2 Germany Pharmacogenomics Technology & Theranostics & Companion Diagnostics (CDx) Market Size and Forecast (2016-2026)
7.3.3 France Pharmacogenomics Technology & Theranostics & Companion Diagnostics (CDx) Market Size and Forecast (2016-2026)
7.3.4 United Kingdom Pharmacogenomics Technology & Theranostics & Companion Diagnostics (CDx) Market Size and Forecast (2016-2026)
7.3.5 Russia Pharmacogenomics Technology & Theranostics & Companion Diagnostics (CDx) Market Size and Forecast (2016-2026)
7.3.6 Italy Pharmacogenomics Technology & Theranostics & Companion Diagnostics (CDx) Market Size and Forecast (2016-2026)
8 Asia-Pacific by Region, by Type, and by Application
8.1 Asia-Pacific Pharmacogenomics Technology & Theranostics & Companion Diagnostics (CDx) Revenue by Type (2016-2026)
8.2 Asia-Pacific Pharmacogenomics Technology & Theranostics & Companion Diagnostics (CDx) Revenue by Application (2016-2026)
8.3 Asia-Pacific Pharmacogenomics Technology & Theranostics & Companion Diagnostics (CDx) Market Size by Region
8.3.1 Asia-Pacific Pharmacogenomics Technology & Theranostics & Companion Diagnostics (CDx) Revenue by Region (2016-2026)
8.3.2 China Pharmacogenomics Technology & Theranostics & Companion Diagnostics (CDx) Market Size and Forecast (2016-2026)
8.3.3 Japan Pharmacogenomics Technology & Theranostics & Companion Diagnostics (CDx) Market Size and Forecast (2016-2026)
8.3.4 South Korea Pharmacogenomics Technology & Theranostics & Companion Diagnostics (CDx) Market Size and Forecast (2016-2026)
8.3.5 India Pharmacogenomics Technology & Theranostics & Companion Diagnostics (CDx) Market Size and Forecast (2016-2026)
8.3.6 Southeast Asia Pharmacogenomics Technology & Theranostics & Companion Diagnostics (CDx) Market Size and Forecast (2016-2026)
8.3.7 Australia Pharmacogenomics Technology & Theranostics & Companion Diagnostics (CDx) Market Size and Forecast (2016-2026)
9 South America by Country, by Type, and by Application
9.1 South America Pharmacogenomics Technology & Theranostics & Companion Diagnostics (CDx) Revenue by Type (2016-2026)
9.2 South America Pharmacogenomics Technology & Theranostics & Companion Diagnostics (CDx) Revenue by Application (2016-2026)
9.3 South America Pharmacogenomics Technology & Theranostics & Companion Diagnostics (CDx) Market Size by Country
9.3.1 South America Pharmacogenomics Technology & Theranostics & Companion Diagnostics (CDx) Revenue by Country (2016-2026)
9.3.2 Brazil Pharmacogenomics Technology & Theranostics & Companion Diagnostics (CDx) Market Size and Forecast (2016-2026)
9.3.3 Argentina Pharmacogenomics Technology & Theranostics & Companion Diagnostics (CDx) Market Size and Forecast (2016-2026)
10 Middle East & Africa by Country, by Type, and by Application
10.1 Middle East & Africa Pharmacogenomics Technology & Theranostics & Companion Diagnostics (CDx) Revenue by Type (2016-2026)
10.2 Middle East & Africa Pharmacogenomics Technology & Theranostics & Companion Diagnostics (CDx) Revenue by Application (2016-2026)
10.3 Middle East & Africa Pharmacogenomics Technology & Theranostics & Companion Diagnostics (CDx) Market Size by Country
10.3.1 Middle East & Africa Pharmacogenomics Technology & Theranostics & Companion Diagnostics (CDx) Revenue by Country (2016-2026)
10.3.2 Turkey Pharmacogenomics Technology & Theranostics & Companion Diagnostics (CDx) Market Size and Forecast (2016-2026)
10.3.3 Saudi Arabia Pharmacogenomics Technology & Theranostics & Companion Diagnostics (CDx) Market Size and Forecast (2016-2026)
10.3.4 UAE Pharmacogenomics Technology & Theranostics & Companion Diagnostics (CDx) Market Size and Forecast (2016-2026)
11 Research Findings and Conclusion
12 Appendix
12.1 Methodology
12.2 Research Process and Data Source
12.3 Disclaimer

List of Tables
Table 1. Global Pharmacogenomics Technology & Theranostics & Companion Diagnostics (CDx) Revenue by Type, (USD Million), 2020 VS 2021 VS 2026
Table 2. Global Pharmacogenomics Technology & Theranostics & Companion Diagnostics (CDx) Revenue by Application, (USD Million), 2020 VS 2021 VS 2026
Table 3. Global Market Pharmacogenomics Technology & Theranostics & Companion Diagnostics (CDx) Revenue (Million USD) Comparison by Region (2016 VS 2021 VS 2026)
Table 4. Global Pharmacogenomics Technology & Theranostics & Companion Diagnostics (CDx) Revenue (USD Million) by Region (2016-2021)
Table 5. Global Pharmacogenomics Technology & Theranostics & Companion Diagnostics (CDx) Revenue Market Share by Region (2021-2026)
Table 6. Qiagen NV Corporate Information, Head Office, and Major Competitors
Table 7. Qiagen NV Major Business
Table 8. Qiagen NV Pharmacogenomics Technology & Theranostics & Companion Diagnostics (CDx) Product and Solutions
Table 9. Qiagen NV Pharmacogenomics Technology & Theranostics & Companion Diagnostics (CDx) Revenue (USD Million), Gross Margin and Market Share (2019-2021)
Table 10. GE Healthcare Corporate Information, Head Office, and Major Competitors
Table 11. GE Healthcare Major Business
Table 12. GE Healthcare Pharmacogenomics Technology & Theranostics & Companion Diagnostics (CDx) Product and Solutions
Table 13. GE Healthcare Pharmacogenomics Technology & Theranostics & Companion Diagnostics (CDx) Revenue (USD Million), Gross Margin and Market Share (2019-2021)
Table 14. Agilent Technologies Corporate Information, Head Office, and Major Competitors
Table 15. Agilent Technologies Major Business
Table 16. Agilent Technologies Pharmacogenomics Technology & Theranostics & Companion Diagnostics (CDx) Product and Solutions
Table 17. Agilent Technologies Pharmacogenomics Technology & Theranostics & Companion Diagnostics (CDx) Revenue (USD Million), Gross Margin and Market Share (2019-2021)
Table 18. F Hoffman La Roche Corporate Information, Head Office, and Major Competitors
Table 19. F Hoffman La Roche Major Business
Table 20. F Hoffman La Roche Pharmacogenomics Technology & Theranostics & Companion Diagnostics (CDx) Product and Solutions
Table 21. F Hoffman La Roche Pharmacogenomics Technology & Theranostics & Companion Diagnostics (CDx) Revenue (USD Million), Gross Margin and Market Share (2019-2021)
Table 22. Foundation Medicine Corporate Information, Head Office, and Major Competitors
Table 23. Foundation Medicine Major Business
Table 24. Foundation Medicine Pharmacogenomics Technology & Theranostics & Companion Diagnostics (CDx) Product and Solutions
Table 25. Foundation Medicine Pharmacogenomics Technology & Theranostics & Companion Diagnostics (CDx) Revenue (USD Million), Gross Margin and Market Share (2019-2021)
Table 26. Thermo Fisher Scientific Inc. Corporate Information, Head Office, and Major Competitors
Table 27. Thermo Fisher Scientific Inc. Major Business
Table 28. Thermo Fisher Scientific Inc. Pharmacogenomics Technology & Theranostics & Companion Diagnostics (CDx) Product and Solutions
Table 29. Thermo Fisher Scientific Inc. Pharmacogenomics Technology & Theranostics & Companion Diagnostics (CDx) Revenue (USD Million), Gross Margin and Market Share (2019-2021)
Table 30. Leica Biosystems Nussloch GmBH Corporate Information, Head Office, and Major Competitors
Table 31. Leica Biosystems Nussloch GmBH Major Business
Table 32. Leica Biosystems Nussloch GmBH Pharmacogenomics Technology & Theranostics & Companion Diagnostics (CDx) Product and Solutions
Table 33. Leica Biosystems Nussloch GmBH Pharmacogenomics Technology & Theranostics & Companion Diagnostics (CDx) Revenue (USD Million), Gross Margin and Market Share (2019-2021)
Table 34. Pfizer Corporate Information, Head Office, and Major Competitors
Table 35. Pfizer Major Business
Table 36. Pfizer Pharmacogenomics Technology & Theranostics & Companion Diagnostics (CDx) Product and Solutions
Table 37. Pfizer Pharmacogenomics Technology & Theranostics & Companion Diagnostics (CDx) Revenue (USD Million), Gross Margin and Market Share (2019-2021)
Table 38. Global Pharmacogenomics Technology & Theranostics & Companion Diagnostics (CDx) Revenue (USD Million) by Players (2019-2021)
Table 39. Global Pharmacogenomics Technology & Theranostics & Companion Diagnostics (CDx) Revenue Share by Players (2019-2021)
Table 40. Breakdown of Pharmacogenomics Technology & Theranostics & Companion Diagnostics (CDx) by Company Type (Tier 1, Tier 2 and Tier 3)
Table 41. Pharmacogenomics Technology & Theranostics & Companion Diagnostics (CDx) Players Head Office, Products and Services Provided
Table 42. Pharmacogenomics Technology & Theranostics & Companion Diagnostics (CDx) Mergers & Acquisitions in the Past Five Years
Table 43. Pharmacogenomics Technology & Theranostics & Companion Diagnostics (CDx) New Entrants and Expansion Plans
Table 44. Global Pharmacogenomics Technology & Theranostics & Companion Diagnostics (CDx) Revenue (USD Million) by Type (2016-2021)
Table 45. Global Pharmacogenomics Technology & Theranostics & Companion Diagnostics (CDx) Revenue Share by Type (2016-2021)
Table 46. Global Pharmacogenomics Technology & Theranostics & Companion Diagnostics (CDx) Revenue Forecast by Type (2021-2026)
Table 47. Global Pharmacogenomics Technology & Theranostics & Companion Diagnostics (CDx) Revenue by Application (2016-2021)
Table 48. Global Pharmacogenomics Technology & Theranostics & Companion Diagnostics (CDx) Revenue Forecast by Application (2021-2026)
Table 49. North America Pharmacogenomics Technology & Theranostics & Companion Diagnostics (CDx) Revenue by Type (2016-2021) & (USD Million)
Table 50. North America Pharmacogenomics Technology & Theranostics & Companion Diagnostics (CDx) Revenue by Type (2021-2026) & (USD Million)
Table 51. North America Pharmacogenomics Technology & Theranostics & Companion Diagnostics (CDx) Revenue by Application (2016-2021) & (USD Million)
Table 52. North America Pharmacogenomics Technology & Theranostics & Companion Diagnostics (CDx) Revenue by Application (2021-2026) & (USD Million)
Table 53. North America Pharmacogenomics Technology & Theranostics & Companion Diagnostics (CDx) Revenue by Country (2016-2021) & (USD Million)
Table 54. North America Pharmacogenomics Technology & Theranostics & Companion Diagnostics (CDx) Revenue by Country (2021-2026) & (USD Million)
Table 55. Europe Pharmacogenomics Technology & Theranostics & Companion Diagnostics (CDx) Revenue by Type (2016-2021) & (USD Million)
Table 56. Europe Pharmacogenomics Technology & Theranostics & Companion Diagnostics (CDx) Revenue by Type (2021-2026) & (USD Million)
Table 57. Europe Pharmacogenomics Technology & Theranostics & Companion Diagnostics (CDx) Revenue by Application (2016-2021) & (USD Million)
Table 58. Europe Pharmacogenomics Technology & Theranostics & Companion Diagnostics (CDx) Revenue by Application (2021-2026) & (USD Million)
Table 59. Europe Pharmacogenomics Technology & Theranostics & Companion Diagnostics (CDx) Revenue by Country (2016-2021) & (USD Million)
Table 60. Europe Pharmacogenomics Technology & Theranostics & Companion Diagnostics (CDx) Revenue by Country (2021-2026) & (USD Million)
Table 61. Asia-Pacific Pharmacogenomics Technology & Theranostics & Companion Diagnostics (CDx) Revenue by Type (2016-2021) & (USD Million)
Table 62. Asia-Pacific Pharmacogenomics Technology & Theranostics & Companion Diagnostics (CDx) Revenue by Type (2021-2026) & (USD Million)
Table 63. Asia-Pacific Pharmacogenomics Technology & Theranostics & Companion Diagnostics (CDx) Revenue by Application (2016-2021) & (USD Million)
Table 64. Asia-Pacific Pharmacogenomics Technology & Theranostics & Companion Diagnostics (CDx) Revenue by Application (2021-2026) & (USD Million)
Table 65. Asia-Pacific Pharmacogenomics Technology & Theranostics & Companion Diagnostics (CDx) Revenue by Region (2016-2021) & (USD Million)
Table 66. Asia-Pacific Pharmacogenomics Technology & Theranostics & Companion Diagnostics (CDx) Revenue by Region (2021-2026) & (USD Million)
Table 67. South America Pharmacogenomics Technology & Theranostics & Companion Diagnostics (CDx) Revenue by Type (2016-2021) & (USD Million)
Table 68. South America Pharmacogenomics Technology & Theranostics & Companion Diagnostics (CDx) Revenue by Type (2021-2026) & (USD Million)
Table 69. South America Pharmacogenomics Technology & Theranostics & Companion Diagnostics (CDx) Revenue by Application (2016-2021) & (USD Million)
Table 70. South America Pharmacogenomics Technology & Theranostics & Companion Diagnostics (CDx) Revenue by Application (2021-2026) & (USD Million)
Table 71. South America Pharmacogenomics Technology & Theranostics & Companion Diagnostics (CDx) Revenue by Country (2016-2021) & (USD Million)
Table 72. South America Pharmacogenomics Technology & Theranostics & Companion Diagnostics (CDx) Revenue by Country (2021-2026) & (USD Million)
Table 73. Middle East & Africa Pharmacogenomics Technology & Theranostics & Companion Diagnostics (CDx) Revenue by Type (2016-2021) & (USD Million)
Table 74. Middle East & Africa Pharmacogenomics Technology & Theranostics & Companion Diagnostics (CDx) Revenue by Type (2021-2026) & (USD Million)
Table 75. Middle East & Africa Pharmacogenomics Technology & Theranostics & Companion Diagnostics (CDx) Revenue by Application (2016-2021) & (USD Million)
Table 76. Middle East & Africa Pharmacogenomics Technology & Theranostics & Companion Diagnostics (CDx) Revenue by Application (2021-2026) & (USD Million)
Table 77. Middle East & Africa Pharmacogenomics Technology & Theranostics & Companion Diagnostics (CDx) Revenue by Country (2016-2021) & (USD Million)
Table 78. Middle East & Africa Pharmacogenomics Technology & Theranostics & Companion Diagnostics (CDx) Revenue by Country (2021-2026) & (USD Million)
List of Figures
Figure 1. Pharmacogenomics Technology & Theranostics & Companion Diagnostics (CDx) Picture
Figure 2. Global Pharmacogenomics Technology & Theranostics & Companion Diagnostics (CDx) Revenue Market Share by Type in 2020
Figure 3. PCR
Figure 4. In-situ Hybridization
Figure 5. Immunohistochemistry
Figure 6. Sequencing
Figure 7. Others
Figure 8. Pharmacogenomics Technology & Theranostics & Companion Diagnostics (CDx) Revenue Market Share by Application in 2020
Figure 9. Oncology Picture
Figure 10. Neurological Disorders Picture
Figure 11. Cardiovascular Disease Picture
Figure 12. Immunological Disorders Picture
Figure 13. Others Picture
Figure 14. Global Pharmacogenomics Technology & Theranostics & Companion Diagnostics (CDx) Revenue, (USD Million): 2020 VS 2021 VS 2026
Figure 15. Global Pharmacogenomics Technology & Theranostics & Companion Diagnostics (CDx) Revenue and Forecast (2016-2026) & (USD Million)
Figure 16. Global Pharmacogenomics Technology & Theranostics & Companion Diagnostics (CDx) Revenue Market Share by Region (2016-2026)
Figure 17. Global Pharmacogenomics Technology & Theranostics & Companion Diagnostics (CDx) Revenue Market Share by Region in 2020
Figure 18. North America Pharmacogenomics Technology & Theranostics & Companion Diagnostics (CDx) Revenue (USD Million) and Growth Rate (2016-2026)
Figure 19. Europe Pharmacogenomics Technology & Theranostics & Companion Diagnostics (CDx) Revenue (USD Million) and Growth Rate (2016-2026)
Figure 20. Asia-Pacific Pharmacogenomics Technology & Theranostics & Companion Diagnostics (CDx) Revenue (USD Million) and Growth Rate (2016-2026)
Figure 21. South America Pharmacogenomics Technology & Theranostics & Companion Diagnostics (CDx) Revenue (USD Million) and Growth Rate (2016-2026)
Figure 22. Middle East and Africa Pharmacogenomics Technology & Theranostics & Companion Diagnostics (CDx) Revenue (USD Million) and Growth Rate (2016-2026)
Figure 23. Pharmacogenomics Technology & Theranostics & Companion Diagnostics (CDx) Market Drivers
Figure 24. Pharmacogenomics Technology & Theranostics & Companion Diagnostics (CDx) Market Restraints
Figure 25. Pharmacogenomics Technology & Theranostics & Companion Diagnostics (CDx) Market Trends
Figure 26. Qiagen NV Recent Developments and Future Plans
Figure 27. GE Healthcare Recent Developments and Future Plans
Figure 28. Agilent Technologies Recent Developments and Future Plans
Figure 29. F Hoffman La Roche Recent Developments and Future Plans
Figure 30. Foundation Medicine Recent Developments and Future Plans
Figure 31. Thermo Fisher Scientific Inc. Recent Developments and Future Plans
Figure 32. Leica Biosystems Nussloch GmBH Recent Developments and Future Plans
Figure 33. Pfizer Recent Developments and Future Plans
Figure 34. Global Pharmacogenomics Technology & Theranostics & Companion Diagnostics (CDx) Revenue Share by Players in 2020
Figure 35. Pharmacogenomics Technology & Theranostics & Companion Diagnostics (CDx) Market Share by Company Type (Tier 1, Tier 2 and Tier 3)
Figure 36. Global Top 3 Players Pharmacogenomics Technology & Theranostics & Companion Diagnostics (CDx) Revenue Market Share in 2020
Figure 37. Global Top 10 Players Pharmacogenomics Technology & Theranostics & Companion Diagnostics (CDx) Revenue Market Share in 2020
Figure 38. Key Players Market Share Trend (Top 3 Market Share: 2019 VS 2020 VS 2021)
Figure 39. Global Pharmacogenomics Technology & Theranostics & Companion Diagnostics (CDx) Revenue Share by Type in 2020
Figure 40. Global Pharmacogenomics Technology & Theranostics & Companion Diagnostics (CDx) Market Share Forecast by Type (2021-2026)
Figure 41. Global Pharmacogenomics Technology & Theranostics & Companion Diagnostics (CDx) Revenue Share by Application in 2020
Figure 42. Global Pharmacogenomics Technology & Theranostics & Companion Diagnostics (CDx) Market Share Forecast by Application (2021-2026)
Figure 43. North America Pharmacogenomics Technology & Theranostics & Companion Diagnostics (CDx) Sales Market Share by Type (2016-2026)
Figure 44. North America Pharmacogenomics Technology & Theranostics & Companion Diagnostics (CDx) Sales Market Share by Application (2016-2026)
Figure 45. North America Pharmacogenomics Technology & Theranostics & Companion Diagnostics (CDx) Revenue Market Share by Country (2016-2026)
Figure 46. United States Pharmacogenomics Technology & Theranostics & Companion Diagnostics (CDx) Revenue and Growth Rate (2016-2026) & (USD Million)
Figure 47. Canada Pharmacogenomics Technology & Theranostics & Companion Diagnostics (CDx) Revenue and Growth Rate (2016-2026) & (USD Million)
Figure 48. Mexico Pharmacogenomics Technology & Theranostics & Companion Diagnostics (CDx) Revenue and Growth Rate (2016-2026) & (USD Million)
Figure 49. Europe Pharmacogenomics Technology & Theranostics & Companion Diagnostics (CDx) Sales Market Share by Type (2016-2026)
Figure 50. Europe Pharmacogenomics Technology & Theranostics & Companion Diagnostics (CDx) Sales Market Share by Application (2016-2026)
Figure 51. Europe Pharmacogenomics Technology & Theranostics & Companion Diagnostics (CDx) Revenue Market Share by Country (2016-2026)
Figure 52. Germany Pharmacogenomics Technology & Theranostics & Companion Diagnostics (CDx) Revenue and Growth Rate (2016-2026) & (USD Million)
Figure 53. France Pharmacogenomics Technology & Theranostics & Companion Diagnostics (CDx) Revenue and Growth Rate (2016-2026) & (USD Million)
Figure 54. United Kingdom Pharmacogenomics Technology & Theranostics & Companion Diagnostics (CDx) Revenue and Growth Rate (2016-2026) & (USD Million)
Figure 55. Russia Pharmacogenomics Technology & Theranostics & Companion Diagnostics (CDx) Revenue and Growth Rate (2016-2026) & (USD Million)
Figure 56. Italy Pharmacogenomics Technology & Theranostics & Companion Diagnostics (CDx) Revenue and Growth Rate (2016-2026) & (USD Million)
Figure 57. Asia-Pacific Pharmacogenomics Technology & Theranostics & Companion Diagnostics (CDx) Sales Market Share by Type (2016-2026)
Figure 58. Asia-Pacific Pharmacogenomics Technology & Theranostics & Companion Diagnostics (CDx) Sales Market Share by Application (2016-2026)
Figure 59. Asia-Pacific Pharmacogenomics Technology & Theranostics & Companion Diagnostics (CDx) Revenue Market Share by Region (2016-2026)
Figure 60. China Pharmacogenomics Technology & Theranostics & Companion Diagnostics (CDx) Revenue and Growth Rate (2016-2026) & (USD Million)
Figure 61. Japan Pharmacogenomics Technology & Theranostics & Companion Diagnostics (CDx) Revenue and Growth Rate (2016-2026) & (USD Million)
Figure 62. South Korea Pharmacogenomics Technology & Theranostics & Companion Diagnostics (CDx) Revenue and Growth Rate (2016-2026) & (USD Million)
Figure 63. India Pharmacogenomics Technology & Theranostics & Companion Diagnostics (CDx) Revenue and Growth Rate (2016-2026) & (USD Million)
Figure 64. Southeast Asia Pharmacogenomics Technology & Theranostics & Companion Diagnostics (CDx) Revenue and Growth Rate (2016-2026) & (USD Million)
Figure 65. Australia Pharmacogenomics Technology & Theranostics & Companion Diagnostics (CDx) Revenue and Growth Rate (2016-2026) & (USD Million)
Figure 66. South America Pharmacogenomics Technology & Theranostics & Companion Diagnostics (CDx) Sales Market Share by Type (2016-2026)
Figure 67. South America Pharmacogenomics Technology & Theranostics & Companion Diagnostics (CDx) Sales Market Share by Application (2016-2026)
Figure 68. South America Pharmacogenomics Technology & Theranostics & Companion Diagnostics (CDx) Revenue Market Share by Country (2016-2026)
Figure 69. Brazil Pharmacogenomics Technology & Theranostics & Companion Diagnostics (CDx) Revenue and Growth Rate (2016-2026) & (USD Million)
Figure 70. Argentina Pharmacogenomics Technology & Theranostics & Companion Diagnostics (CDx) Revenue and Growth Rate (2016-2026) & (USD Million)
Figure 71. Middle East and Africa Pharmacogenomics Technology & Theranostics & Companion Diagnostics (CDx) Sales Market Share by Type (2016-2026)
Figure 72. Middle East and Africa Pharmacogenomics Technology & Theranostics & Companion Diagnostics (CDx) Sales Market Share by Application (2016-2026)
Figure 73. Middle East and Africa Pharmacogenomics Technology & Theranostics & Companion Diagnostics (CDx) Revenue Market Share by Country (2016-2026)
Figure 74. Turkey Pharmacogenomics Technology & Theranostics & Companion Diagnostics (CDx) Revenue and Growth Rate (2016-2026) & (USD Million)
Figure 75. Saudi Arabia Pharmacogenomics Technology & Theranostics & Companion Diagnostics (CDx) Revenue and Growth Rate (2016-2026) & (USD Million)
Figure 76. UAE Pharmacogenomics Technology & Theranostics & Companion Diagnostics (CDx) Revenue and Growth Rate (2016-2026) & (USD Million)
Figure 77. Methodology
Figure 78. Research Process and Data Source

---